HYTRIN-7 TABS 1MG-7 TABS 2MG-14 TABS 5MG KIT

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

TERAZOSIN (TERAZOSIN HYDROCHLORIDE); TERAZOSIN (TERAZOSIN HYDROCHLORIDE); TERAZOSIN (TERAZOSIN HYDROCHLORIDE)

Disponible depuis:

ABBOTT LABORATORIES, LIMITED

Code ATC:

G04CA03

DCI (Dénomination commune internationale):

TERAZOSIN

Dosage:

1MG; 2MG; 5MG

forme pharmaceutique:

KIT

Composition:

TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 1MG; TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 2MG; TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 5MG

Mode d'administration:

ORAL

Unités en paquet:

1 EA

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ALPHA-ADRENERGIC BLOCKING AGENTS

Descriptif du produit:

Active ingredient group (AIG) number: 0336814001; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2006-10-17

Résumé des caractéristiques du produit

_ _
_HYTRIN® Product Monograph _
_Page 1 of 37_
PRODUCT MONOGRAPH
Pr
HYTRIN
®
terazosin hydrochloride
1, 2, 5 and 10 mg tablets
Antihypertensive Agent
Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
Abbott Laboratories, Limited
8401 Trans-Canada Highway
St. Laurent (Quebec) Canada
H4S 1Z1
Date of Preparation:
May 15, 1997
Date of Revision:
June 15, 2006
Submission Control No: 104433
_ _
_HYTRIN® Product Monograph _
_Page 2 of 37_
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND
ADMINISTRATION..............................................................................15
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND
STABILITY..........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL
INFORMATION..........................................................................20
CLINICAL
TRIALS..........................................................................................................21
DETAILED
PHARMACOLOGY....................................